In the Media

InMed’s cannabinol (CBN) formulation for glaucoma – Executive Interview with CEO Eric A. Adams

In this video, InMed Pharmaceuticals CEO Eric A. Adams speaks about the company’s ocular disease program. INM-088 is a cannabinol (CBN) formulation showing potential to reduce intraocular pressure and neuroprotection of the eye, important for glaucoma and several other eye diseases. InMed has conducted a number of preclinical studies of CBN, comparing it against several cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). CBN demonstrated the most optimal effect for glaucoma over other cannabinoids.

Source: Edison TV

Share this post

Latest Media News